Payment overview · 2025
General Payments
$253.98
8 reported records · 7 companies
Healthcare provider profile · identity verified
David Hoyt
Allopathic & Osteopathic Physicians|Family Medicine · MERCER, PA · NPI 1245209469
Verified facts
What the public records show
CMS Open Payments records show David Hoyt received $253.98 in general payments during 2025 across 8 reported records.
Novo Nordisk Inc accounted for 49.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Synthroid by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 288 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $124.99 | 49.2% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $32.46 | 12.8% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $23.36 | 9.2% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $21.40 | 8.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.93 | 7.5% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $16.94 | 6.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.90 | 6.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $253.98 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $32.46 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN Normalized: watchman |
Device | Boston Scientific Corporation | $23.36 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.93 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.93 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $16.94 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 288 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
94 | 27 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
288 | 61 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1052 | 272 |
| Levothyroxine Sodium | Levothyroxine Sodium | 944 | 231 |
| Pantoprazole Sodium | Pantoprazole Sodium | 763 | 203 |
| Metformin Hcl | Metformin Hcl | 748 | 213 |
| Lisinopril | Lisinopril | 737 | 202 |
| Eliquis | Apixaban | 735 | 108 |
| Amlodipine Besylate | Amlodipine Besylate | 657 | 164 |
| Potassium Chloride | Potassium Chloride | 632 | 133 |
| Gabapentin | Gabapentin | 611 | 136 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 529 | 151 |
| Tamsulosin Hcl | Tamsulosin Hcl | 499 | 123 |
| Carvedilol | Carvedilol | 474 | 86 |
| Furosemide | Furosemide | 470 | 94 |
| Omeprazole | Omeprazole | 464 | 111 |
| Simvastatin | Simvastatin | 449 | 122 |
| Meloxicam | Meloxicam | 395 | 144 |
| Metoprolol Tartrate | Metoprolol Tartrate | 353 | 94 |
| Pravastatin Sodium | Pravastatin Sodium | 339 | 88 |
| Metoprolol Succinate | Metoprolol Succinate | 335 | 66 |
| Losartan Potassium | Losartan Potassium | 315 | 85 |
| Famotidine | Famotidine | 312 | 77 |
| Allopurinol | Allopurinol | 300 | 77 |
| Glimepiride | Glimepiride | 297 | 84 |
| Duloxetine Hcl | Duloxetine Hcl | 294 | 66 |
| Clopidogrel | Clopidogrel Bisulfate | 290 | 69 |
| Escitalopram Oxalate | Escitalopram Oxalate | 290 | 67 |
| Ozempic | Semaglutide | 288 | 61 |
| Donepezil Hcl | Donepezil Hcl | 251 | 29 |
| Trazodone Hcl | Trazodone Hcl | 248 | 57 |
| Bumetanide | Bumetanide | 241 | 62 |
| Sertraline Hcl | Sertraline Hcl | 239 | 57 |
| Fluticasone Propionate | Fluticasone Propionate | 225 | 100 |
| Valsartan | Valsartan | 215 | 59 |
| Buspirone Hcl | Buspirone Hcl | 208 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 179 | 55 |
| Mounjaro | Tirzepatide | 175 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 174 | 65 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 164 | 49 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 161 | 40 |
| Atenolol | Atenolol | 159 | 46 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 155 | 36 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 152 | 43 |
| Spironolactone | Spironolactone | 151 | 38 |
| Alendronate Sodium | Alendronate Sodium | 149 | 38 |
| Tramadol Hcl | Tramadol Hcl | 149 | 49 |
| Diclofenac Sodium | Diclofenac Sodium | 147 | 44 |
| Hydralazine Hcl | Hydralazine Hcl | 145 | 36 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 135 | 39 |
| Jardiance | Empagliflozin | 134 | 27 |
| Lorazepam | Lorazepam | 133 | 41 |
| Benazepril Hcl | Benazepril Hcl | 124 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 118 | 23 |
| Amoxicillin | Amoxicillin | 116 | 104 |
| Xarelto | Rivaroxaban | 115 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 114 | 30 |
| Baclofen | Baclofen | 112 | 47 |
| Celecoxib | Celecoxib | 111 | 30 |
| Sucralfate | Sucralfate | 111 | 29 |
| Trulicity | Dulaglutide | 111 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 110 | 14 |
| Memantine Hcl | Memantine Hcl | 109 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 105 | 32 |
| Doxycycline Hyclate | Doxycycline Hyclate | 104 | 89 |
| Methylprednisolone | Methylprednisolone | 104 | 90 |
| Cefuroxime | Cefuroxime Axetil | 102 | 77 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 102 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 101 | 19 |
| Pregabalin | Pregabalin | 100 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 99 | 27 |
| Torsemide | Torsemide | 96 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 94 | 80 |
| Digoxin | Digoxin | 94 | 22 |
| Synthroid | Levothyroxine Sodium | 94 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 91 | 23 |
| Montelukast Sodium | Montelukast Sodium | 90 | 25 |
| Prednisone | Prednisone | 90 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 88 | 17 |
| Tradjenta | Linagliptin | 88 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 84 | 20 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 84 | 19 |
| Ezetimibe | Ezetimibe | 82 | 21 |
| Meclizine Hcl | Meclizine Hcl | 82 | 40 |
| Fluoxetine Hcl | Fluoxetine Hcl | 81 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 79 | 22 |
| Glipizide | Glipizide | 78 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 76 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 76 | 23 |
| Azithromycin | Azithromycin | 75 | 60 |
| Humalog Kwikpen U-100 | Insulin Lispro | 75 | 16 |
| Mirtazapine | Mirtazapine | 75 | 26 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 75 | 52 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 75 | 14 |
| Levetiracetam | Levetiracetam | 73 | 14 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 73 | suppressed |
| Humalog | Insulin Lispro | 72 | suppressed |
| Etodolac | Etodolac | 70 | 22 |
| Novolog Flexpen | Insulin Aspart | 69 | 18 |
| Colestipol Hcl | Colestipol Hcl | 68 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 68 | 17 |
| Naproxen | Naproxen | 67 | 19 |
| Ibuprofen | Ibuprofen | 66 | 20 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 65 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 65 | 18 |
| Clonidine Hcl | Clonidine Hcl | 62 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 61 | 14 |
| Alprazolam | Alprazolam | 59 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 58 | 51 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 56 | 40 |
| Amiodarone Hcl | Amiodarone Hcl | 55 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 55 | suppressed |
| Scopolamine | Scopolamine | 55 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 54 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 53 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | suppressed |
| Gemtesa | Vibegron | 51 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 50 | 14 |
| Enalapril Maleate | Enalapril Maleate | 49 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 49 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 47 | 32 |
| Valacyclovir | Valacyclovir Hcl | 47 | 22 |
| Propranolol Hcl Er | Propranolol Hcl | 45 | 12 |
| Sulindac | Sulindac | 45 | 13 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 43 | 16 |
| Topiramate | Topiramate | 41 | 13 |
| Bupropion Xl | Bupropion Hcl | 40 | suppressed |
| Nystatin | Nystatin | 40 | 21 |
| Nitroglycerin | Nitroglycerin | 38 | 23 |
| Clonazepam | Clonazepam | 37 | suppressed |
| Lansoprazole | Lansoprazole | 37 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 35 | suppressed |
| Fenofibrate | Fenofibrate | 34 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 34 | suppressed |
| Entresto | Sacubitril/Valsartan | 33 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 33 | 31 |
| Verapamil Er | Verapamil Hcl | 33 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 32 | 14 |
| Dutasteride | Dutasteride | 32 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 32 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 31 | suppressed |
| Fluconazole | Fluconazole | 31 | 25 |
| Methocarbamol | Methocarbamol | 31 | suppressed |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | 11 |
| Eszopiclone | Eszopiclone | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Estradiol | Estradiol | 29 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 28 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 28 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | 11 |
| Loperamide | Loperamide Hcl | 28 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 28 | suppressed |
| Repatha Sureclick | Evolocumab | 28 | suppressed |
| Rybelsus | Semaglutide | 28 | suppressed |
| Cephalexin | Cephalexin | 27 | 18 |
| Glipizide Er | Glipizide | 27 | suppressed |
| Methotrexate | Methotrexate Sodium | 27 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 27 | suppressed |
| Klor-Con M20 | Potassium Chloride | 26 | 11 |
| Theophylline Er | Theophylline Anhydrous | 26 | suppressed |
| Actemra | Tocilizumab | 25 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Gemfibrozil | Gemfibrozil | 24 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 23 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 23 | suppressed |
| Latanoprost | Latanoprost | 23 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 23 | suppressed |
| Carbamazepine | Carbamazepine | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | suppressed |
| Colchicine | Colchicine | 21 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 21 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 21 | suppressed |
| Premarin | Estrogens, Conjugated | 21 | suppressed |
| Cartia Xt | Diltiazem Hcl | 20 | 11 |
| Diazepam | Diazepam | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 18 | suppressed |
| Pentoxifylline | Pentoxifylline | 18 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 17 | suppressed |
| Jantoven | Warfarin Sodium | 17 | suppressed |
| Klor-Con 10 | Potassium Chloride | 17 | suppressed |
| Nabumetone | Nabumetone | 17 | suppressed |
| Anastrozole | Anastrozole | 16 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 15 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 11 |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Novolog | Insulin Aspart | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Clarithromycin | Clarithromycin | 14 | 11 |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Oxazepam | Oxazepam | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Cimetidine | Cimetidine | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Pimozide | Pimozide | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | 11 |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Np Thyroid | Thyroid,pork | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Tivicay | Dolutegravir Sodium | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Nexium | Esomeprazole Magnesium | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $253.98 · 8 records | Novo Nordisk Inc | INSPIRE, JOURNAVX, Kerendia, LEQVIO, Ozempic, QULIPTA, UBRELVY, WATCHMAN | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error